(R)-N-[2,3-Dihydro-1-[2-(2-methylphenyl)-2-oxoethyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-N'-(3-methylphenyl)-urea

Product Name(R)-N-[2,3-Dihydro-1-[2-(2-methylphenyl)-2-oxoethyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-N'-(3-methylphenyl)-urea
CAS145084-28-2
MFC32H28N4O3
MW516.59
EINECS
MOL File145084-28-2.mol

Chemical Properties

Melting point	187-190 °C
Boiling point	735.4±60.0 °C(Predicted)
Density	1.23±0.1 g/cm3(Predicted)
storage temp.	Store at RT
solubility	DMSO: soluble5mg/mL (clear solution)
form	powder
pka	11.61±0.40(Predicted)
color	white to beige
optical activity	[α]/D -128 to -140 (c = 1, DCM)
InChIKey	YCXFHPUBGMMWJQ-PMERELPUSA-N
SMILES	Cc1cccc(NC(=O)N[C@@H]2N=C(c3ccccc3)c4ccccc4N(CC(=O)c5ccccc5C)C2=O)c1

Safety Information

Hazard Codes	T
Risk Statements	25
Safety Statements	45
RIDADR	UN 2811 6.1 / PGIII
WGK Germany	3
Storage Class	6.1C - Combustible acute toxic Cat.3 toxic compounds or compounds which causing chronic effects
Hazard Classifications	Acute Tox. 3 Oral

Usage And Synthesis

Uses

YM 022, is a potent, selective non-peptide antagonist of the gastrin/cholecystokinin (CCK)-B receptor. (Ki values are 68 pM and 63 nM at CCK2 and CCK1 receptors respectively).

Biological Activity

Extremely potent and highly selective non-peptide CCK 2 silent antagonist (K i values are 68 pM and 63 nM at CCK 2 and CCK 1 receptors respectively). Acts in vivo to potently inhibit gastrin-induced gastric acid secretion and histidine decarboxylase activation with a long duration of action.

in vivo

YM022 (intravenous injection; 0.01-1 μM/kg) dose-dependently inhibits pentagastrin- and peptone meal-induced acid secretion with ED₅₀ values of 0.0261 and 0.0654 μmol/kg, respectively, without affecting histamine- or methacholine-induced acid secretion^[3].
YM022 (subcutaneous injection; 300 μmol/kg; single dose) lowers the oxyntic mucosal HDC activity and raises the serum gastrin concentration in a dose-dependent manner (measured 24 h after dosage). Maximum enzyme inhibition is achieved at a dose of 300 μmol/kg for YM022 and the inhibition of HDC lasts for 4 weeks. At sacrifice, drug residues can be seen at the injection site for as long as 4 (YM022) weeks after injection in rat^[3].
YM022 is suspended in 2% Methocel for oral ingestion and in PEG300 for subcutaneous injection^[3].

Animal Model:	Rat^[3]
Dosage:	300 μmol/kg
Administration:	Subcutaneous injection; 300 μmol/kg; single dose
Result:	Suppressed the ECL cell activity for at least 4 as manifested in greatly reduced HDC activity, greatly elevated serum gastrin level.

IC 50

CCR2: 68 pM (Ki); CCR1: 63 nM (Ki)

storage

Store at RT

(R)-N-[2,3-Dihydro-1-[2-(2-methylphenyl)-2-oxoethyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-N'-(3-methylphenyl)-urea Supplier

(R)-N-[2,3-Dihydro-1-[2-(2-methylphenyl)-2-oxoethyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-N'-(3-methylphenyl)-urea manufacturers

Related Product Information

Send Inquriy